An elegant study by Debruyne and colleagues demonstrated that ALK-mutated, MYCN-amplified neuroblastoma cells that develop resistance to ALK inhibition had elevated BORIS expression and altered chromatin looping interactions. The gene discussed is ALK; the disease is neuroblastoma.